Targeting SLC5A2 suppresses colorectal tumour development by enhancing NK cell activity through extracellular vesicle-dependent MICA/B signalling - PubMed
7 hours ago
- #NK cells
- #SLC5A2
- #colorectal cancer
- Targeting SLC5A2 with dapagliflozin suppresses colorectal tumor development.
- SLC5A2 inhibition enhances NK cell activity via EV-associated MICA/B signaling.
- Clinical samples show an inverse link between SLC5A2 expression and NK cell infiltration.
- SLC5A2 alters membrane potential and calcium influx, boosting MICA/B secretion in EVs.
- Dapagliflozin emerges as a potential therapeutic for CRC, especially in metabolic comorbidities.